Kodiak Sciences (NASDAQ:KOD) Shares Down 5.9% - Here's What Happened
Kodiak Sciences (NASDAQ:KOD) saw its stock price drop by 5.9% on Friday, with significantly lower trading volume than average. Despite the dip, analysts generally maintain a "Moderate Buy" consensus rating with an average price target of $28.29. Additionally, a director recently made a substantial insider purchase of 2,608,696 shares, increasing their holdings to over 18 million shares.
GSA Capital Partners LLP Sells 76,735 Shares of Kodiak Sciences Inc. $KOD
GSA Capital Partners LLP significantly reduced its stake in Kodiak Sciences Inc. by selling over 76,000 shares in Q3. Despite this, other institutional investors have increased their holdings, and a director also made a substantial share acquisition. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $28.29.
H.C. Wainwright reiterates Buy rating on Kodiak Sciences stock at $38 By Investing.com
H.C. Wainwright has reaffirmed its Buy rating and a $38.00 price target for Kodiak Sciences Inc. (NASDAQ:KOD), following positive final results from the Phase 1B APEX trial for its KSI-101 treatment. The analyst firm anticipates 2026 to be a "pivotal catalyst-rich" year for the company, with ongoing advancements for KSI-101 and other pipeline developments. Despite a 355% return over the past year, InvestingPro analysis suggests the stock might currently be overvalued.
H.C. Wainwright reiterates Buy rating on Kodiak Sciences stock at $38
H.C. Wainwright has reiterated its Buy rating and $38 price target for Kodiak Sciences Inc. (NASDAQ:KOD) following positive final Phase 1B APEX trial results for its KSI-101 treatment. The analyst firm anticipates a "pivotal catalyst-rich" year for Kodiak Sciences, with a 56% upside from the current stock price, despite InvestingPro suggesting potential overvaluation. The company also recently closed a public offering raising $184 million and has other clinical developments underway.
KOD: HC Wainwright & Co. Reiterates Buy Rating with $38 Target | KOD Stock News
HC Wainwright & Co. has reiterated its Buy rating for Kodiak Sciences (KOD) with an unchanged price target of $38.00. This follows a previous price target increase on January 22, 2026, and reflects the analyst's continued confidence in the biopharmaceutical company despite no recent target adjustments. Kodiak Sciences, specializing in treatments for high-prevalence retinal diseases, has an average analyst price target of $30.71, suggesting a 26.24% upside from its current price.
HC Wainwright Reaffirms Buy Rating for Kodiak Sciences (NASDAQ:KOD)
HC Wainwright has reaffirmed a "Buy" rating for Kodiak Sciences (NASDAQ:KOD), setting a $38 price target that suggests a 56% upside. The company, a clinical-stage biopharmaceutical firm focusing on retinal diseases, shows significant insider and institutional ownership. While analyst consensus is a "Moderate Buy," Kodiak Sciences reported negative earnings per share last quarter and for the current fiscal year estimate.
H.C. Wainwright reiterates Buy rating on Kodiak Sciences stock at $38
H.C. Wainwright has reiterated its Buy rating and $38 price target for Kodiak Sciences Inc. (NASDAQ:KOD) after the company presented final Phase 1B APEX trial results for its KSI-101 treatment. The trial results, which focused on treating macular edema secondary to inflammation (MESI), showed positive anatomical and visual improvements. Despite a wide range of analyst targets, Kodiak Sciences is embarking on a "pivotal catalyst-rich" year with ongoing Phase 3 trials and developments across multiple drug candidates.
KOD Stock Up 24% in 3 Months: Here's What You Need to Know
Kodiak Sciences (KOD) shares have risen 24% in the last three months, driven by strong progress in its late-stage pipeline programs for various retinal diseases. The company's lead candidates, tarcocimab, KSI-501, and KSI-101, are advancing through pivotal Phase III studies, with key data readouts anticipated in 2026 and 2027. Additionally, a successful equity offering in December 2025 significantly bolstered its financial position, extending its cash runway and further boosting investor confidence despite its early commercial stage.
Kodiak Sciences to present final APEX study results at Angiogenesis meeting
Kodiak Sciences Inc. (NASDAQ:KOD) will present final clinical results from its Phase 1b APEX study of KSI-101 for macular edema secondary to inflammation (MESI) at the virtual Angiogenesis annual meeting on February 7, 2026. The company's stock has surged over 316% in the past year, and KSI-101 is currently in two Phase 3 trials. Topline data from the PEAK study is expected in Q4 2026, and PINNACLE results in Q2 2027.
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Average Recommendation of "Moderate Buy" from Brokerages
Kodiak Sciences Inc. (NASDAQ:KOD) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 1-year target price of $28.29. This positive outlook follows a significant insider purchase of 2.6 million shares by Director Bros. Advisors LP and comes despite the company reporting an EPS loss for the last quarter. Kodiak Sciences, a clinical-stage biopharmaceutical company focusing on retinal diseases, is trading down by 6.9% at $22.38.
Kodiak Sciences (KOD) Price Target Increased by 11.69% to 31.33
The average one-year price target for Kodiak Sciences (KOD) has increased by 11.69% to $31.33 per share. This target is an average of analyst predictions, ranging from $2.02 to $52.50, and represents a 30.37% increase from the last closing price. Institutional ownership in Kodiak Sciences has risen, with major holders including Baker Bros. Advisors and Point72 Asset Management increasing or maintaining significant stakes.
Kodiak Sciences raises capital through completed stock offering
Kodiak Sciences recently completed a securities offering, raising capital through the sale of its stock. This move is aimed at strengthening the company's financial position, potentially to fund ongoing research and development or other corporate initiatives. The successful offering indicates investor confidence in Kodiak Sciences' future prospects.
Can Kodiak Sciences (KOD) Funding And Readouts Reshape Its Retinal Disease Treatment Narrative?
H.C. Wainwright reiterated a positive rating on Kodiak Sciences (KOD) following a significant capital raise, expressing confidence in upcoming clinical trial readouts for its retinal disease candidates, tarcocimab and KSI-101. The company's strategy involves leveraging its biopolymer platform to reduce treatment burden for conditions like wet age-related macular degeneration and diabetic macular edema. Despite recent gains and analyst support, Kodiak still faces challenges such as no revenue, rising losses, and a "going concern" note, making trial outcomes and regulatory progress crucial short-term catalysts, with its stock remaining sensitive to new data and financing.
Can Kodiak Sciences (KOD) Funding And Readouts Reshape Its Retinal Disease Treatment Narrative?
H.C. Wainwright has reiterated a positive rating for Kodiak Sciences, citing confidence in upcoming clinical trial readouts for tarcocimab and KSI-101, alongside recent capital raises totaling over US$344 million. Despite no current revenue and rising losses, the company's biopolymer platform aims to reduce treatment burden for retinal diseases. The investment narrative for Kodiak hinges on successful trial outcomes and regulatory progress, driving significant stock volatility.
FY2025 EPS Estimates for Kodiak Sciences Lifted by Analyst
HC Wainwright has updated its FY2025 EPS estimates for Kodiak Sciences, raising them from ($4.35) to ($4.29) while maintaining a "Buy" rating and a $38.00 price target. This adjustment reflects a slightly improved outlook for FY2029 losses, though some near-term EPS forecasts for 2026 and beyond were lowered. Insider activity is significant, with Director Bros. Advisors LP increasing their stake, leading to 45.9% insider ownership.
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 7.6% - Here's Why
Kodiak Sciences' stock price dropped 7.6% on Friday, trading at $25.92 on light volume. Despite a "Moderate Buy" consensus from analysts with a target of $28.29, opinions vary widely, with some downgrades to "sell" ratings. A significant insider purchase by Director Bros. Advisors LP highlights strong insider ownership, even as the company missed its recent EPS estimates.
Kodiak Sciences stock price target raised to $38 from $26 at H.C. Wainwright By Investing.com
H.C. Wainwright has increased its price target for Kodiak Sciences Inc. (NASDAQ:KOD) to $38 from $26, reiterating a Buy rating. This adjustment comes ahead of significant clinical trial readouts for their anti-VEGF candidates, tarcocimab and KSI-101, which are expected to address limitations in current retinal therapies. The company recently closed a public offering raising $184 million and secured a $30 million debt facility, enhancing its financial position for future advancements.
Kodiak Sciences stock price target raised to $38 from $26 at H.C. Wainwright
H.C. Wainwright has increased its price target for Kodiak Sciences Inc. (NASDAQ:KOD) from $26 to $38, maintaining a Buy rating. This adjustment comes ahead of several pivotal clinical trial readouts expected in 2026, including Phase 3 GLOW2 results for tarcocimab and Phase 1b APEX trial data for KSI-101. The firm also raised its probability of success for tarcocimab and KSI-501 in wet AMD, citing confidence in Kodiak's ABC platform and the potential of its candidates to improve upon existing anti-VEGF therapies.
Kodiak Sciences stock price target raised to $38 from $26 at H.C. Wainwright
H.C. Wainwright has raised its price target for Kodiak Sciences Inc. (NASDAQ:KOD) to $38.00 from $26.00, while maintaining a Buy rating. This adjustment comes ahead of several pivotal clinical trial readouts expected this year, including Phase 3 GLOW2 and DAYBREAK results. The firm cited strong confidence in Kodiak's ABC platform and the potential of its candidates to address limitations in current retinal therapies.
Kodiak Sciences (KOD) Valuation Check As Phase 3 Readouts And Capital Raise Focus Investor Attention
Kodiak Sciences (KOD) has completed patient enrollment for its Phase 3 diabetic retinopathy trial, with topline data expected in Q1 2026 and wet AMD results in Q2 2026. Following a recent capital raise and significant share price increase, the market is now focused on these upcoming trial readouts and the company's valuation. While Kodiak's Price-to-Book ratio of 69.7x is high compared to peers, its discounted cash flow (DCF) model suggests a potential 17% discount from its fair value of US$32.27, prompting questions about its true valuation given no meaningful revenue and ongoing losses.
First Week of December 18th Options Trading For Kodiak Sciences (KOD)
Kodiak Sciences Inc. (KOD) has new options contracts available for the December 18th expiration. This article analyzes a specific put option at a $27.00 strike price and a call option at a $32.00 strike price, highlighting potential strategies like selling puts for income or executing covered calls, and calculating the potential YieldBoost for each. It also considers the probability of these options expiring worthless based on current analytical data and outlines the implied and trailing twelve-month volatility.
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 7.7% - Here's What Happened
Kodiak Sciences (NASDAQ:KOD) saw its stock price drop by 7.7% to $25.59 on Monday, with trading volume significantly lower than average. This decline occurred despite a recent large insider purchase of 2.6 million shares by Director Bros. Advisors Lp Baker worth approximately $60 million, increasing insider ownership to 45.90%. The company faces mixed analyst ratings, a "Moderate Buy" consensus with a target price of $26.57, and recently missed quarterly earnings expectations.
A Look At Kodiak Sciences (KOD) Valuation After Strong Recent Share Price Momentum
Kodiak Sciences (KOD) has experienced strong share price momentum, with a 90-day return of 138.97% and a 1-year return of 233.17%. While the company is flagged with a high Price-to-Book ratio of 72.5x compared to an industry average of 2.7x, suggesting overvaluation, Simply Wall St's Discounted Cash Flow (DCF) model indicates the stock is 15.1% undervalued with a fair value of US$32.63 per share. The article highlights the conflicting signals from the P/B ratio and the DCF model, posing a key question for investors regarding the justification of the high P/B multiple for an early-stage biopharma company with no revenue and a net loss.
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Average Rating of "Moderate Buy" from Analysts
Kodiak Sciences Inc. (NASDAQ:KOD) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $26.57. This rating is based on reports from eight firms, including five buy ratings, two holds, and one sell. A significant insider purchase was noted, with Director Bros. Advisors LP acquiring 2,608,696 shares for approximately $60 million, increasing their stake to over 18 million shares. The company's shares are currently trading around $27.72, and it recently missed quarterly EPS estimates, reporting -$1.16 against an expected -$1.07.
Is Kodiak Sciences (KOD) Pricing Reflect Recent Biotech Pipeline And Funding Developments Accurately
Kodiak Sciences (KOD) has seen significant share price movements, including a 194.2% gain over the last year, driven by biotech pipeline progress and financing updates. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 17.4% at US$32.77 per share compared to its recent price of US$27.07, while its Price-to-Book ratio of 70.81x significantly exceeds industry averages. The article encourages investors to consider different "Narratives" for valuation, integrating their own assumptions about future performance.
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Kodiak Sciences Inc. (Nasdaq: KOD), a retina-focused biotechnology company, announced that its senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 1:30 p.m. Pacific Time. The company is developing three late-stage clinical programs for retinal diseases, with topline data readouts expected in 2026 and 2027. A live webcast of the presentation will be available on Kodiak’s website.
UBS Initiates Coverage of Kodiak Sciences (KOD) with Buy Recommendation
UBS has initiated coverage on Kodiak Sciences (KOD) with a Buy recommendation. Despite this, the average one-year price target suggests a 9.84% downside from its current closing price. Institutional ownership in Kodiak Sciences has increased, with several key funds holding significant positions.
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Kodiak Sciences Inc. (Nasdaq: KOD), a biotechnology company focused on retinal therapeutics, announced its senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 1:30 p.m. Pacific Time. A live webcast will be available on the company's website. Kodiak is developing a portfolio of three late-stage clinical programs for retinal vascular diseases and macular edema.
UBS initiates Kodiak Sciences stock with Buy rating, $50 price target
UBS has initiated coverage on Kodiak Sciences Inc. (NASDAQ:KOD) with a Buy rating and a $50 price target, projecting nearly 100% upside. The investment bank anticipates a catalyst-rich 2026 for Kodiak, with three major Phase III clinical trial readouts expected throughout the year for its drugs tarcocimab and KSI-101, which together could represent over $2 billion in risk-adjusted value. This positive outlook follows recent financial activities, including a public stock offering and a new debt facility, aimed at enhancing the company's liquidity and financial flexibility.
UBS initiates Kodiak Sciences stock with Buy rating, $50 price target
UBS has initiated coverage on Kodiak Sciences Inc. (NASDAQ:KOD) with a Buy rating and a $50 price target, citing a rich catalyst year in 2026 with three major Phase III clinical trial readouts expected. The investment bank believes positive results from these trials, particularly for tarcocimab and KSI-101, could drive significant upside for the stock, with a combined valuation potential of $2-2.5 billion. Kodiak Sciences has also recently engaged in several public offerings and secured a new debt facility to enhance its financial position.
Kodiak Sciences stock hits 52-week high at $29.52
Kodiak Sciences (KOD) stock reached a new 52-week high of $29.52, reflecting a 178.12% increase over the past year and an impressive 660.39% over six months. This surge is driven by advancements in its drug development pipeline and strategic partnerships, despite the company's high volatility and current unprofitability. The company recently closed a public offering raising approximately $184 million, and H.C. Wainwright raised its price target for KOD, citing upcoming Phase 3 GLOW2 trial data as a significant catalyst.
Kodiak Sciences stock hits 52-week high at $29.52 By Investing.com
Kodiak Sciences Inc. (KOD) stock has reached a new 52-week high of $29.52, driven by a 178.12% increase over the past year and a 660.39% return in the last six months. This surge follows the successful closure of a public offering that raised $184 million and an increased price target from H.C. Wainwright, who maintains a "Buy" rating based on anticipated clinical trial results. Despite high volatility and current unprofitability, the company's advancements in its drug development pipeline continue to attract investor confidence.
Kodiak Sciences Stock Surge: An In-Depth Look
Kodiak Sciences Inc.'s (NASDAQ: KOD) stock experienced a 13.22% surge following an upsized underwritten offering of nearly 7 million shares at $23 each, aimed at securing $160 million. This move, expected to close on December 18, 2025, reflects investor confidence in the company's advancements in wet AMD treatment and its strategic financial planning despite recent losses in cash flow. The article delves into Kodiak's financial health, market perception, and future prospects, emphasizing the bold investments in research for pharmaceutical innovation.
Kodiak Sciences (NASDAQ:KOD) Shares Up 6% - Here's Why
Kodiak Sciences (NASDAQ:KOD) shares rose 6% on Wednesday, trading as high as $28.50 with a closing price of $29.10 on light volume. This surge follows a significant insider purchase where Director Bros. Advisors LP Baker acquired over 2.6 million shares for approximately $60 million, increasing their stake to 18.3 million shares. Analyst ratings for KOD are mixed, with a consensus "Hold" rating and a $22.67 price target, though some recent upgrades and an "outperform" rating with a $40 target have been noted.
Kodiak Sciences (NASDAQ:KOD) Shares Gap Up After Insider Buying Activity
Kodiak Sciences (NASDAQ:KOD) shares gapped up following an insider buying activity where Director Bros. Advisors LP Baker purchased 2,608,696 shares for approximately $60 million. This acquisition increased their stake by 16.56% and propelled the stock to open at $27.95 after closing at $26.00, subsequently trading around $28.24. Despite the positive market reaction, analyst ratings are mixed, with a consensus "Hold" rating and a target price below the current trading value.
Kodiak Sciences (KOD): Assessing Valuation After Its $160 Million Capital Raise for Late-Stage Pipeline
Kodiak Sciences (KOD) recently completed a $160 million stock offering to fund its late-stage eye disease drug programs, following significant share price growth (73.22% in 90 days, 201.62% YTD) despite a long-term decline. The company's valuation, evidenced by a high price-to-book ratio of 58.1x, suggests strong market optimism for its retinal disease pipeline despite unprofitability and a considerable premium over industry averages. This raises questions about whether the market is overestimating future growth or if more upside remains.
Kodiak Sciences (KOD): Assessing Valuation After Its $160 Million Capital Raise for Late-Stage Pipeline
Kodiak Sciences recently completed a $160 million capital raise to fund its late-stage eye disease drug programs, following a significant surge in its stock price. Despite strong recent momentum, the company's valuation appears high, with a price-to-book ratio of 58.1x, significantly exceeding industry averages. This premium valuation suggests strong market optimism for its retinal disease pipeline, but also indicates potential overvaluation given its current unprofitability.
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
The article reviews four biotech stocks—Ionis Pharmaceuticals, Structure Therapeutics, Monopar Therapeutics, and Kodiak Sciences—that more than doubled in 2025 due to improved sentiment and specific company catalysts. It details their recent clinical achievements, regulatory milestones, and commercial progress, while also discussing their prospects for sustaining growth into 2026. Each company's stock is currently rated as a Zacks Rank #3 (Hold), but they have generally seen favorable earnings estimate revisions.
Bros. Advisors Lp Baker Buys 2,608,696 Shares of Kodiak Sciences (NASDAQ:KOD) Stock
Bros. Advisors Lp Baker purchased 2,608,696 shares of Kodiak Sciences (NASDAQ:KOD) stock on December 18th for $60 million, increasing their stake to over 18 million shares. This comes as Kodiak Sciences' shares dropped 1.4% on heavy trading volume, and the company missed its quarterly EPS estimates, with analysts projecting a full-year EPS of -3.45. Despite a mixed analyst outlook, the firm has an average "Hold" rating and a consensus target price of $22.67.
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Kodiak Sciences Inc. announced the closing of its $184 million underwritten public offering of common stock, including the full exercise of the underwriters' option to purchase additional shares. This strengthens the company's financial position as it progresses with late-stage clinical trials for KSI-101, KSI-501, and tarcocimab. J.P. Morgan, Jefferies, Evercore ISI, and UBS Investment Bank managed the offering.
Kodiak Sciences closes $184 million public offering of common stock
Kodiak Sciences Inc. announced the closing of its public offering, raising approximately $184 million by selling 8 million shares at $23.00 each, including the underwriters' full exercise of their option for additional shares. This strengthens the company's financial position ahead of crucial Phase 3 trial readouts for its retina-focused pipeline. The stock has seen a recent increase, and analysts like H.C. Wainwright have upgraded its rating due to positive trial data.
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Kodiak Sciences Inc. (Nasdaq: KOD) has successfully closed a public offering of 8,000,000 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares, raising approximately $184 million in gross proceeds. This offering strengthens the company's financial position ahead of key Phase 3 clinical trial readouts for its late-stage assets KSI-101, KSI-501, and tarcocimab. The biotechnology company focuses on developing transformative therapeutics for retinal diseases.
Kodiak Sciences closes $184 million public offering of common stock By Investing.com
Kodiak Sciences Inc. announced the closing of its public offering, raising approximately $184 million through the sale of 8 million shares at $23.00 each. The offering strengthens the company's financial position as it progresses with late-stage clinical assets for retinal diseases. This development follows recent positive analyst upgrades and data from clinical trials.
Retina biotech raises $184M in stock sale as late-stage drug trials loom
Kodiak Sciences closed an underwritten public offering, raising approximately $184 million from the sale of 8,000,000 common shares at $23.00 each, including the full exercise of underwriters' option. This funding will strengthen the company's financial position as it advances toward Phase 3 topline readouts for its late-stage clinical assets KSI-101, KSI-501, and tarcocimab, which are therapies for retinal diseases. The transaction reflects a disciplined approach to capital formation aimed at long-term shareholder value.
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Kodiak Sciences Inc. announced the closing of its underwritten public offering, generating approximately $184 million in gross proceeds. This offering included the full exercise of the underwriters' option to purchase additional shares. The company plans to use these funds to strengthen its financial position as it advances its three late-stage clinical assets through Phase 3 trials.
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Kodiak Sciences Inc. announced the closing of its $184 million underwritten public offering, including the underwriters' full exercise of their option to purchase additional shares. This offering strengthens the company's financial position as it progresses with Phase 3 clinical readouts for its three late-stage assets: KSI-101, KSI-501, and tarcocimab. The company focuses on developing transformative therapeutics for retinal diseases.
Kodiak Sciences Inc. (NASDAQ:KOD) Given Average Rating of "Hold" by Brokerages
Kodiak Sciences Inc. (NASDAQ:KOD) has received an average "Hold" rating from seven brokerages, with an average 12-month price target of $22.67. Institutional investors hold approximately 89.06% of the stock, and several funds significantly increased their positions in Q3. The clinical-stage biopharmaceutical company's shares are currently trading near $24.13, with a market capitalization of $1.28 billion, and its lead candidate KSI-301 is in late-stage trials for retinal diseases.
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Kodiak Sciences Inc. announced the closing of its $184 million public offering of common stock, including the full exercise of the underwriters' option to purchase additional shares. The offering, which sold 8,000,000 shares at $23.00 per share, strengthens the company's financial position ahead of Phase 3 topline readouts for its late-stage clinical assets. J.P. Morgan, Jefferies, Evercore ISI, and UBS Investment Bank served as joint book-running managers for the offering.
Kodiak Sciences stock hits 52-week high at 26.43 USD
Kodiak Sciences Inc. (KOD) (KOD) has reached a 52-week high of $26.43, marking a 175.77% surge over the past year and reflecting strong market confidence. This achievement follows an upsized public offering aimed at raising $160 million and a stock rating upgrade from H.C. Wainwright to "Buy", with increased price targets due to positive clinical trial data. The biotech firm's robust performance highlights its potential and strong investor interest, driven by ongoing clinical developments and strategic financial maneuvers.
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
Kodiak Sciences Inc. announced the pricing of an upsized underwritten public offering of 6,956,522 shares of its common stock at $23.00 per share, expecting to generate approximately $160 million in gross proceeds. The offering is anticipated to close around December 18, 2025, with an option for underwriters to purchase additional shares. J.P. Morgan, Jefferies, Evercore ISI, and UBS Investment Bank are managing the offering.
